There is also supporting evidence indicating that the reduction in expression levels of PVT1 (Plasmacytoma Variant Translocation 1), MALAT1 (Metastasis-Associated Lung Adenocarcinoma Transcript 1), and PCAT-1 (Prostate Cancer-Associated Transcript 1) renders CRC cells more responsive to 5-FU treatment. This evidence concerns the gene PCAT1 and colorectal carcinoma.